NASDAQ: URGNUrogen Pharma Ltd Stock
$20.46+0.85 (+4.33%)
Updated Mar 6, 2026
URGN Price
$20.46
Fair Value Price
N/A
Market Cap
$996.04M
52 Week Low
$3.42
52 Week High
$30.00
P/E
-6.41x
P/B
-9.44x
P/S
10.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$109.79M
Earnings
-$153.49M
Gross Margin
88.7%
Operating Margin
-125.76%
Profit Margin
-139.8%
Debt to Equity
-2.9
Operating Cash Flow
-$162M
Beta
0.88
Next Earnings
May 7, 2026
Ex-Dividend
N/A
Next Dividend
N/A
URGN Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine URGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
URGN
Ranked#112 of 477
Ranked#112 of 477
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.85 | A | |
| $15.44 | A | |
| $182.01 | A |
Be the first to know about important URGN news, forecast changes, insider trades & much more!
URGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how URGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
URGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
URGN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
URGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more URGN due diligence checks available for Premium users.
Valuation
URGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.41x
Industry
34.38x
Market
37.34x
URGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.44x
Industry
4.78x
URGN's financial health
Profit margin
Revenue
$37.8M
Net Income
-$26.4M
Profit Margin
-69.7%
URGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
URGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$200.5M
Liabilities
$305.9M
Debt to equity
-2.9
URGN's short-term assets ($186.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
URGN's long-term liabilities ($259.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
URGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
URGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$38.3M
Investing
$27.7M
Financing
$31.3M
URGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
URGN vs Biotech Stocks
Urogen Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.